Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Yongwaizhengjie Street 17th, Donghu District, Nanchang, Jiangxi, China.
Nanchang University, Nanchang, Jiangxi, China.
Biomed Eng Online. 2022 Jun 27;21(1):42. doi: 10.1186/s12938-022-01011-9.
It is known that inflammatory bowel disease is the result of a defective immune system, and immunotherapy and biological therapy have gradually become important means to treat it. This paper focused on the bibliometric statistical analysis of the current research progress to summarize the research status of this field and analyze the research trends in recent years.
Two visualization tools, CiteSpace and VOSviewer, were used to explore the data of journals, institutions, countries/regions, authors, references, and keywords for the literature included in the Web of Science Core Collection from January 1, 2002, to December 31, 2021.
A total of 312 papers were published in 120 journals by 603 institutions from 40 countries/regions, with 9463 co-cited references. The United States has the most publications with the highest total citations in the world. Inflammatory Bowel Diseases published the maximum number of papers, and Gastroenterology devoted the most co-citations to immunotherapy and biological therapy for IBD. In addition, we found that the studies before 2009 mostly focused on clinical trials while researchers have paid more attention to clinical management in therapy for IBD since 2009. Combination therapy and management of the treatment for the disease have become research hotspots.
The focus of immunotherapy and biotherapy for IBD has shifted from clinical trials to the management of the risks and benefits of immunotherapy.
已知炎症性肠病是免疫系统缺陷的结果，免疫疗法和生物疗法已逐渐成为治疗该病的重要手段。本文聚焦于该领域当前研究进展的文献计量统计分析，以总结该领域的研究现状，并分析近年来的研究趋势。
利用 CiteSpace 和 VOSviewer 这两种可视化工具，对 Web of Science 核心合集收录的 2002 年 1 月 1 日至 2021 年 12 月 31 日期间的文献进行期刊、机构、国家/地区、作者、参考文献和关键词的数据探索。
共检索到 312 篇发表于 120 种期刊的文献，这些文献来自 40 个国家/地区的 603 个机构，被引频次高达 9463 次。其中，美国发表的文献数量最多，全球总被引频次最高。在发表文献最多的期刊中，《炎症性肠病》位列第一，而在被引频次最高的期刊中，《胃肠病学》则是对炎症性肠病的免疫治疗和生物治疗引用最多的期刊。此外，我们发现，2009 年之前的研究主要集中在临床试验上，而自 2009 年以来，研究人员更加关注炎症性肠病的临床管理治疗。联合治疗和疾病治疗管理已成为研究热点。
炎症性肠病的免疫治疗和生物治疗的重点已经从临床试验转向免疫治疗的风险和收益管理。
